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Abstract
The serine protease inhibitor phenylmethylsulfonyl fluoride is shown to cause partial inhibition of bilitranslocase
transport activity in rat liver plasma membrane vesicles. This condition can be fully reversed by means of pyridine-2-al-
doxime methiodide, indicating that the carrier has undergone sulfonylation. Protection against inactivation is afforded by
both bilirubin, the natural substrate, and nicotinic acid, but, unexpectedly, by neither sulfobromophthalein, the chromophoric
substrate employed in bilitranslocase transport activity assay, nor rifamycin SV, a competitive inhibitor of sulfobromoph-
thalein transport. From these protection experiments, the K for the complex of bilitranslocase with either bilirubin ord
nicotinic acid has been estimated to be 2.1 and 10.8 nM, respectively. Tentatively, the target for phenylmethylsulfonyl
fluoride on bilitranslocase is identified as a recognition site for the physiological substrates.
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1. Introduction
Bilirubin is a yellow pigment that is found in
plasma, mainly as a complex with serum albumin. It
is the end product of heme catabolism and is dis-
posed of in the bile. Thus, the liver is the site of its
uptake from the circulation, its chemical modification
to a polar mono- or diglucuronide derivative, and its
excretion into the biliary tract. The first step of
bilirubin metabolism in the liver is its transport across
the plasma membrane, at the sinusoidal pole of the
Abbreviations: BSP, sulfobromophthalein; DTNB, 5,5’-dithio-
 .bis 2-nitrobenzoic acid ; 2-ME, 2-mercaptoethanol; 2-PAM, pyri-
dine-2-aldoxime methiodide; PMSF, phenylmethylsulfonyl fluo-
ride.
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liver cell. At this level, a 37 kDa membrane protein,
w xcalled bilitranslocase 1 , has been identified as the
specific bilirubin carrier. This peptide has been shown
to be a necessary and sufficient ingredient to carry
out the electrogenic movement of bilirubin analogues
 w xin different experimental models see 2 for a recent
.review . During the course of a molecular biology
study aimed at the elucidation of the primary struc-
ture of this protein, a portion of the sequence at-
tracted our attention in that it was characterized by a
relative abundance of hydrophilic residues with a
high propensity for ß sheet configuration. This sug-
gested that this portion should most probably have an
external exposure. In this segment three serine
residues were found. On the assumption that this
external portion of the protein could have an impor-
tant functional role, we have undertaken an investiga-
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tion of the effect of a typical serine-modifier, such as
PMSF, on the transport activity of the carrier. Data
will be presented in this paper showing that PMSF
exerts a dose-dependent inhibitory action on the
transport function; the inhibition can be reversed by
2-PAM, a known antidote in organophosphoric poi-
soning; and, more interestingly, unconjugated biliru-
bin and nicotinate, presumably the physiological sub-
strates for the carrier, exert a potent protective effect
against arylsulfonylation by PMSF. The kinetic anal-
ysis of this effect has allowed to derive a K valued
for the complexes bilirubin-bilitranslocase and nicoti-
nate-bilitranslocase of the order of 2 and 10 nM,
respectively.
2. Materials and methods
Rat liver plasma membrane vesicles were prepared
w xaccording to van Amelsvoort et al. 3 .
 .PMSF Sigma, St. Louis, MO solutions were in
 .DMSO Carlo Erba, Milano, Italy .
The effect of PMSF on bilitranslocase transport
activity was examined by pre-incubating vesicles 1
mg proteinrml, 10 mM Hepes pH 7.4, 0.25 M
.sucrose at 368C. Reactions were started by the addi-
tion of the reagent. DMSO concentration in the sus-
 .pension did never exceed the value of 1% vrv .
Measurements of bilitranslocase transport activity
were performed by the spectrophotometric technique
w xpreviously described 4 . The test was carried out by
the addition of 10 ml of preincubated vesicles to a
cuvette, containing 2 ml assay medium, under stirring
conditions, at room temperature. The assay medium
composition was 0.1 M potassium phosphate buffer
pH 8.0, containing 38 mM BSP. Bilitranslocase
transport activity is triggered by the Kq diffusion
potential generated by the addition of 10 mg valino-
 .mycin Sigma, St. Louis, MO , dissolved in methanol.
The initial rate of the absorbance drop, monitored at
the wavelength-pair 580–514.4 nm, has been shown
to be linearly related to bilitranslocase-mediated elec-
w xtrophoretic entry of BSP into vesicles 4,5 .
Protein determination was carried out by the Brad-
w xford method 6 . All chemicals were of the highest
purity commercially available.
3. Results
The effect of PMSF on the transport activity of
bilitranslocase has been tested by pre-incubating rat
liver plasma membrane vesicles in the presence of a
series of PMSF concentrations. Fig. 1A shows the
results of this experiment. A progressive decay of
transport activity is observed, whose rate appears to
depend on the reagent concentration.
In panel B of Fig. 1 it is shown that the inactiva-
tion rate constant is linearly related to PMSF concen-
tration. The derived second-order rate constant is
107.66 My1 miny1.
The deflection from linearity observed above 0.75
mM PMSF could be simply explained on the basis of
the inhibitor limited solubility in the aqueous medium
 .  .  .Fig. 1. Effect of PMSF on bilitranslocase transport activity. A Kinetics of transport inactivation in the presence of 0.125 ‘ . 0.25 v ,
 .  .  .  .0.5 ^ , 0.75 ’ and 1.0 I mM PMSF. B Inactivation rate constant as a function of reagent concentration. The experimental
conditions are described under Section 2.
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Fig. 2. Kinetics of bilitranslocase inactivation by PMSF. Effect of
PMSF in the preincubation and in the assay medium. Experimen-
tal conditions: curve a: vesicles have been incubated in the
presence of 0.325 mM PMSF and have been assayed either in the
 .  .absence B or in the presence \ of 0.325 mM PMSF; curve
b: vesicles have been incubated in the presence of 0.65 mM
 .PMSF and have been assayed either in the absence v or in the
 .presence ^ of 0.65 mM PMSF.
w x7 . A less trivial explanation could be invoked, such
as the formation of a reversible complex with the
w xreagent, prior to covalent modification 8,9 .
This hypothesis has been tested in the next experi-
ment. Vesicles have been incubated with two differ-
ent concentrations of the reagent. Their transport
activity has been measured under two conditions. In
the first one, the sample is diluted 200-fold in the
assay mixture, so to cause the reagent’s dissociation
from the hypothetical complex, while in the second
one the reagent’s concentration is the same both in
the pre-incubation and in the transport assay vessels,
to avoid any possible dissociation of the complex.
The results in Fig. 2 show that measurements of
transport activity, whether performed in the absence
Fig. 3. Bilitranslocase inactivation by PMSF and effects of the
subsequent addition of either 2-PAM or 2-ME. Experimental
conditions: vesicles have been incubated in the presence of 0.6
mM PMSF. At the time indicated by the arrow either 1.25 mM
 .  .2-PAM B or 14.2 mM ’ 2-ME was added.
or in the presence of the reagent, give data that fit the
same curve. It is concluded therefore that PMSF
makes no reversible complex with bilitranslocase prior
to covalent modification.
In order to obtain information about the kind of
covalent bond introduced in the carrier, reactivation
experiments have been attempted. Two kinds of reac-
tivators have been used. The first is 2-PAM, a strong
nucleophile which reacts with the sulphur atom of
sulfonylated proteins and thus displaces the inhibitor
w xfrom the protein 10 . The second is 2-ME, a nucle-
ophile expected to attack the same atom at the level
w xof a thiosulfonyl ester bond 11 . Their effect on
bilitranslocase transport activity is shown in Fig. 3. It
can be seen that 2-PAM causes the activity to restore
completely, whereas excess 2-ME is ineffective.
These data allow to conclude that the covalent modi-
Fig. 4. Effects of either bilirubin or nicotinic acid on the rate constant of bilitranslocase inactivation by PMSF. Experimental conditions:
 .vesicles have been incubated in the presence of 0.51 mM PMSF with increasing concentrations of either bilirubin A or nicotinic acid
 .B .
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 .  .Fig. 5. Scrutton and Utter plot of bilitranslocase inactivation by PMSF in the presence of either bilirubin A or nicotinic acid B . These
 .  .plots have been constructed with the data of Fig. 4. k , k A and k B refer to the inactivation rate constants obtained either in theo br NA
absence or in the presence of bilirubin or nicotinic acid, respectively.
fication at the basis of bilitranslocase inactivation is
sulfonylation at residues other than cysteines.
The target of the PMSF effect has been investi-
gated through protection experiments. The kinetics of
transport inactivation could, in fact, be different when
observed either in the absence or in the presence of
ligands to bilitranslocase, as already observed with
w xother functional group-reagents 12,13 . Vesicles have
therefore been incubated with PMSF in the presence
of increasing concentrations of the following ligands:
bilirubin, nicotinic acid, BSP and rifamycin SV.
Fig. 4 collates the data obtained with bilirubin and
nicotinic acid, showing the ligand concentration-de-
pendence of the inactivation rate constant decrease.
At the highest concentrations tested, protection is
nearly complete. The data of Fig. 4 have been plotted
w xaccording to the equation of Scrutton and Utter 14 :
k rk s k rk qK 1y k rk r a .  .  .a o 2 1 d a o
where k and k are the inactivation rate constantsa o
obtained in the presence and in the absence of the
anionic ligand, respectively; k rk is the ratio of the2 1
rate constants for the reaction of the bilitranslocase-
 .  .ligand complex k and free bilitranslocase k with2 1
the reagent, K is the dissociation constant for thed
w xligand and a is the ligand concentration.
The plots are shown in Fig. 5. With both ligands, a
straight line is obtained, passing through the origin.
This indicates that the rate constant for the reaction
of the carrier-ligand complex is zero and makes it
clear that the complex is not involved in the reaction.
From the slopes, the values of the dissociation con-
stants of the two complexes are obtained. These are
2.1 nM and 10.8 nM, for bilirubin and nicotinic acid,
respectively.
The same experiments, performed with either BSP
or rifamycin SV, have revealed no protection effect at
 .all data not shown .
Finally, the effect of ligands has been tested also
on the kinetics of reactivation. As a matter of fact,
when bilitranslocase was inactivated with both cys-
teine- and arginine-specific reagents, reactivation
could be accelerated by the presence of these ligands
w x12,13 . Therefore, vesicles have been exposed to
 .1.25 mM 2-PAM Fig. 6, squares , either in the
absence or in the presence of 20 nM bilirubin. It is
seen that the reactivation kinetics is not affected by
bilirubin. Under these conditions, the reactivation rate
Fig. 6. Time course of bilitranslocase inactivation by PMSF and
of reactivation induced by 2-PAM either in the absence or in the
presence of bilirubin. Experimental conditions: vesicles have
been incubated with 0.6 mM PMSF. At the time indicated by the
 .  .arrow, 1.25 mM without I or with B 20 nM bilirubin has
been added; the same experiment has been performed also with
 .  .0.25 mM 2-PAM without ^ and with ’ 20 nM bilirubin.
( )S. Passamonti et al.rBiochimica et Biophysica Acta 1323 1997 130–136134
might be maximal, so that the bilirubin effect could
pass unnoticed. However, this is missing also when
reactivation, induced by 0.25 mM 2-PAM, proceeds
 .at a remarkably lower pace Fig. 6, triangles .
4. Discussion
The data presented above show that PMSF acts as
an inhibitor of bilitranslocase transport activity in rat
liver plasma membrane vesicles. The mechanism of
inactivation does not include the formation of a re-
versible bilitranslocase-PMSF complex.
Inactivation can be fully reversed by a nucleophile,
such as 2-PAM, allowing to conclude that a sulfonyl
w xester bond has been formed on the carrier protein 9 .
However, S-sulfonylation is ruled out by the fact that
w x2-ME fails to reactivate 11 .
The protective effect of both bilirubin and nico-
tinic acid permit to infer that the site of sulfonylation
has an important, physiological role. This is corrob-
orated by the very low bilirubin concentration, about
10 nM, affording complete protection and the derived
 .K value 2.1 nM for the carrier-bilirubin complex,d
at the level of the sulfonylation site. Attention may be
drawn on the fact that the bilirubin effect is observed
within the pigment’s solubility limit in water at pH
w x7.4 15 . Therefore, there is no need to supply the
system with albumin and the interpretation of the
results is straightforward.
The results obtained with nicotinic acid are quite
interesting for a number of reasons. Its protective
effect is exerted through a very low K value 10.8d
.nM, only 5-fold higher than that of bilirubin , raising
the issue that bilitranslocase could be the door for the
entry of this vitamin precursor into the liver. More-
over, these data confirm earlier observations concern-
ing the inhibitory effect of this anion on BSP trans-
port activity and its competitive binding on purified
w xbilitranslocase 16 .
The fact that neither BSP nor rifamycin SV pro-
vided a protective effect comes as an acute note of
peculiarity of the PMSF target in bilitranslocase, the
more so since BSP translocation is indeed affected,
though only partially.
This entire phenomenonology could indicate that
the site of sulfonylation is within a segment of the
protein devoted to the exclusive binding of bilirubin
 .or its strictest analogue, nicotinic acid . None the
less, sulfonylation of this segment affects the function
of BSP translocation, possibly as a consequence of a
conformational adjustment or steric hindrance by the
adduct.
Thus, by the use of PMSF, we have found that
bilitranslocase contains a portion of its sequence that
can operate a fine discrimination among its sub-
strates. In particular, the discrimination is operated
among natural, physiological compounds and xenobi-
otic molecules.
These features make quite possible that this site
occupies a strategical position in the protein, perhaps
on an ectodomain at the sinusoidal surface of the cell
membrane. At this level, free bilirubin could find a
specific, high-affinity binding site, representing the
first step of the translocation process into the liver
cell.
If indeed the segment in question represents the
portion of the carrier conferring the high affinity for
its physiological substrate, it is reasonably expected
that a modification at this level would drastically
reduce the ability of the carrier to operate the uptake
of unconjugated bilirubin under physiological condi-
tions. As a matter of fact, the impairment of bilirubin
uptake might occur even in the presence of mild
reduction of the carrier activity with respect to other
substrates, commonly used in the experimentation.
This consideration calls therefore for a word of cau-
tion when comparing results obtained in different
experimental models, measuring the rates of transport
of either bilirubin or phthaleins. This becomes of
paramount importance when PMSF is included in the
isolation media during subfractionation of the tissue,
to forestall proteolysis.
As to the identity of the sulfonylation site, this
might be, in the first place, a serine. Other sites,
however, cannot be disregarded a priori; for instance,
threonine and tyrosine could lend their hydroxyl and
w xhistidine its imidazole 17 .
The fact that 2-ME did not cause reactivation
stands as a proof that none of the functionally rele-
vant thiol groups of bilitranslocase has participated in
the reaction.
In this regard, it might turn useful to examine the
effects of sulfonylation, as opposed to those of thiol-
w xand arginine-modification 12,13 , on bilitranslocase
transport function. For simplicity, only the DTNB-
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Table 1
Bilitranslocase modification by phenylglyoxal, DTNB and PMSF
Effects Phenylglyoxal DTNB PMSF
Extent of inactivation 50% 50% 30%
a aProtective ligands all all some
Induced reactivation yes yes yes
Acceleration of reactivation yes yes no
by ligands
a Nicotinic acid not tested.
w xsensitive 12 class of thiols is surveyed. The facts to
be examined are summarized in Table 1.
Thiol- and arginine-modification has common fea-
w xtures and additional evidence 18 has been provided
that the DTNB-sensitive cysteine and the arginine
 .  .are: a close to each other and b belonging to a
common functional domain of the carrier. By con-
trast, sulfonylation is a different event, that causes no
more than 30% loss of activity, is prevented only by
the natural substrates and induced reactivation cannot
be speeded up by the presence of ligands. All of these
considerations focus on the fact that the site of
sulfonylation has functional properties quite distinct
from those of the site of either cysteine- or arginine-
specific modification. This segment plays a critical
role in the binding of bilirubin, or nicotinic acid; its
chemical modification causes only limited disorder to
the transport process of BSP into the vesicle.
It cannot be forgotten that other transport proteins
have been found to occur in the rat liver plasma
membrane fraction, which employ BSP as a substrate
 w x .see 19 for a review . Of course, PMSF could cause
their covalent modification, possibly with inhibition
of their BSP transport function. If the rate of BSP
entry into vesicles, as collected by our method, were
the measure of a sum of of BSP transporters, then the
overall rate of PMSF inhibition would be the sum of
a number of individual modification reactions. Were
this the case, the rate of PMSF inactivation would not
appear as a simple, pseudo-first order process, unless
all transporters reacted with the reagent at the same
rate. Also the protection data indicate that a single
binding site for either bilirubin or nicotinic acid is
located with these experiments. This is proven by the
fact that plotting the data of Fig. 4 according to the
Scrutton and Utter equation results in a simple,
straight line. A more complex pattern should arise if
either bilirubin or nicotinic acid exerted protection
upon a variety of binding sites with their own binding
affinities. The effect of PMSF on the rate of BSP
transport in vesicles is ascribed to the modification of
bilitranslocase on the basis of the established rela-
tionship between the electrogenic BSP uptake by
w xvesicles and the purified protein 5 . Further, direct
proof of bilitranslocase covalent modification by this
reagent is currently under test in our laboratory.
A last word should be spent about the widespread
use of PMSF in buffer solutions, as an inhibitor of
protease activity. This work shows that this reagent
has a wide spectrum of activity, because it appears
that reactive serines are not confined to the categories
of serine-proteases or esterases. Thus, its employment
should pass an experimental test of inoffensiveness.
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